Mikael Brönnegård
Director/Board Member at Biopart Venture AB
Profile
Mikael Brönnegård is currently a Director at Biopart Venture AB and Gothia Förlag AB.
He was previously the CEO & Investor Relations Contact at Abliva AB from 2012 to 2015.
He also held positions as Chief Executive Officer at ISR Immune System Regulation Holding AB, Director at IdMos Plc from 2007 to 2007, and Director at Quiatech AB.
Brönnegård obtained a doctorate degree from Karolinska Institutet.
Mikael Brönnegård active positions
Companies | Position | Start |
---|---|---|
Biopart Venture AB | Director/Board Member | 01/01/2001 |
Gothia Förlag AB
Gothia Förlag AB Commercial Printing/FormsCommercial Services Gothia Förlag AB is a publishing private company based in Stockholm, Sweden. The Swedish company provides publishing services. | Director/Board Member | 01/01/2006 |
Former positions of Mikael Brönnegård
Companies | Position | End |
---|---|---|
ABLIVA AB | Chief Executive Officer | 01/09/2015 |
Quiatech AB
Quiatech AB Pharmaceuticals: MajorHealth Technology Quiatech AB develops and manufactures drugs. It is a research based company that develops enabling technologies for genetic analysis, molecular diagnostics, and gene-based therapeutics in the expanding market of DNA technologies that offer significant improvements in the quality of DNA microarray and other DNA oligonucleotide data. It has also developed a new modified RNA chemistry (Qt RNA Technology) utilizing a novel 2 protecting group on the RNA amidites, this development greatly improves the synthesis conditions, producing fully functional RNA at high yields. It is headquartered in Uppsala, Sweden. | Director/Board Member | 30/08/2007 |
IdMos Plc
IdMos Plc Medical SpecialtiesHealth Technology IdMos Plc engages in research, development and commercialization of its disease detection and monitoring technology. The company is headquartered in Dundee, the United Kingdom. | Director/Board Member | 01/01/2007 |
ISR IMMUNE SYSTEM REGULATION HOLDING AB (PUBL) | Chief Executive Officer | - |
Training of Mikael Brönnegård
Karolinska Institutet | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
ABLIVA AB | Health Technology |
Private companies | 5 |
---|---|
IdMos Plc
IdMos Plc Medical SpecialtiesHealth Technology IdMos Plc engages in research, development and commercialization of its disease detection and monitoring technology. The company is headquartered in Dundee, the United Kingdom. | Health Technology |
Quiatech AB
Quiatech AB Pharmaceuticals: MajorHealth Technology Quiatech AB develops and manufactures drugs. It is a research based company that develops enabling technologies for genetic analysis, molecular diagnostics, and gene-based therapeutics in the expanding market of DNA technologies that offer significant improvements in the quality of DNA microarray and other DNA oligonucleotide data. It has also developed a new modified RNA chemistry (Qt RNA Technology) utilizing a novel 2 protecting group on the RNA amidites, this development greatly improves the synthesis conditions, producing fully functional RNA at high yields. It is headquartered in Uppsala, Sweden. | Health Technology |
Biopart Venture AB | |
Gothia Förlag AB
Gothia Förlag AB Commercial Printing/FormsCommercial Services Gothia Förlag AB is a publishing private company based in Stockholm, Sweden. The Swedish company provides publishing services. | Commercial Services |
ISR Immune System Regulation Holding AB
ISR Immune System Regulation Holding AB Pharmaceuticals: MajorHealth Technology ISR Immune System Regulation Holding AB engages in pharmaceutical research for the treatment of viral diseases focusing on Human Immunodeficiency Virus (HIV). It is developing ISR048 for the novel treatment of HIV. The company was founded by Yen Lundgren and Ulf Ljungblad in September 17, 2015 and is headquartered in Solna, Sweden. | Health Technology |
- Stock Market
- Insiders
- Mikael Brönnegård